- INMD Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
-
Insider
- Institutional
- Shorts
-
CORRESP Filing
InMode (INMD) CORRESPCorrespondence with SEC
Filed: 12 Jan 21, 12:00am
![]() | Mayer Brown LLP 1221 Avenue of the Americas New York, NY 10020-1001 United States of America T: +1 212 506 2500 F: +1 212 262 1910 mayerbrown.com |
January 12, 2021 | |
VIA EDGAR AND OVERNIGHT DELIVERY | |
U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Tracie Mariner and Mr. Kevin Vaughn Re: InMode Ltd. Form 20-F for Fiscal Year Ended December 31, 2019 Filed February 18, 2020 File No. 001-09016 |
1. | Please revise your future filings to more clearly disclose the reasons for the changes in your results of operations between periods and address the following: |
• | Expand your disclosure of operating results to quantify the extent to which increases in sales volumes versus prices contributed to the increases in net sales and cost of sales. |
• | Expand your disclosure to quantify the impact of other factors you identified as contributing to fluctuations in the line items impacting net income. For example, you attribute the increase in research and development expense to an increase in cost of raw materials and subcontractors and an increase in spending on clinical studies without quantifying the increase of each item. |
• | Refer to Item 303(a)(3)(iii) of Regulation S-K and Rule Release 33-8350 for guidance. |
2. | In future filings, please expand your disclosure of cash provided by operating activities to quantify and discuss the underlying reasons for the changes in working capital items reported in your Statements of Cash Flows. Refer to FRC Section 501.13.b and 13.b.1 for guidance. |
cc: | Brian D. Hirshberg |